Compare OPRA & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OPRA | VERA |
|---|---|---|
| Founded | 1996 | 2016 |
| Country | Norway | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 2.5B |
| IPO Year | 2018 | 2021 |
| Metric | OPRA | VERA |
|---|---|---|
| Price | $18.07 | $31.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $21.50 | ★ $81.30 |
| AVG Volume (30 Days) | 316.8K | ★ 1.0M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.61% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $21.29 | N/A |
| Revenue Next Year | $15.34 | $472.48 |
| P/E Ratio | $13.62 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.71 | $19.07 |
| 52 Week High | $21.06 | $56.05 |
| Indicator | OPRA | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 51.36 | 38.63 |
| Support Level | $13.08 | $27.19 |
| Resistance Level | $19.24 | $31.92 |
| Average True Range (ATR) | 0.62 | 2.24 |
| MACD | -0.04 | -0.16 |
| Stochastic Oscillator | 50.57 | 18.76 |
Opera Ltd is a consumer internet software company providing a diversified portfolio of high-performance web browsers and adjacent digital services to engaged user base The company has transitioned from browser developer to multi-faceted platform offering a products and services that include PC and mobile browsers, its Opera Gaming portals and development tools, Opera News content platforms, Opera Ads platform, as well as a number of AI and web3 products and services, such as MiniPay and Opera AI, to a user base.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.